Development and validation of a clinically applicable score to classify cachexia stages in advanced cancer patients
Open Access
- 25 January 2018
- journal article
- research article
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 9 (2) , 306-314
Abstract
Background: Cachexia is a multifactorial syndrome that is highly prevalent in advanced cancer patients and leads to progressive functional impairments. The classification of cachexia stages is essential for diagnosing and treating cachexia. However, there is a lack of simple tools with good discrimination for classifying cachexia stages. Therefore, our study aimed to develop a clinically applicable cachexia staging score (CSS) and validate its discrimination of clinical outcomes for different cachexia stages.Methods: Advanced cancer patients were enrolled in our study. A CSS comprising the following five components was developed: weight loss, a simple questionnaire of sarcopenia (SARC‐F), Eastern Cooperative Oncology Group, appetite loss, and abnormal biochemistry. According to the CSS, patients were classified into non‐cachexia, pre‐cachexia, cachexia, and refractory cachexia stages, and clinical outcomes were compared among the four groups.Results: Of the 297 participating patients, data from 259 patients were ultimately included. Based on the CSS, patients were classified into non‐cachexia (n = 69), pre‐cachexia (n = 68), cachexia (n = 103), and refractory cachexia (n = 19) stages. Patients with more severe cachexia stages had lower skeletal muscle indexes (P = 0.002 and P = 0.004 in male and female patients, respectively), higher prevalence of sarcopenia (P = 0.017 and P = 0.027 in male and female patients, respectively), more severe symptom burden (P < 0.001), poorer quality of life (P < 0.001 for all subscales except social well‐being), and shorter survival times (P < 0.001).Conclusions: The CSS is a simple and clinically applicable tool with excellent discrimination for classifying cachexia stages. This score is extremely useful for the clinical treatment and prognosis of cachexia and for designing clinical trials.Keywords
Funding Information
- National Natural Science Foundation of China (81372852, 11602155)
This publication has 46 references indexed in Scilit:
- The applicability of a weight loss grading system in cancer cachexia: a longitudinal analysisJournal of Cachexia, Sarcopenia and Muscle, 2017
- The influence of different muscle mass measurements on the diagnosis of cancer cachexiaJournal of Cachexia, Sarcopenia and Muscle, 2017
- Validation of the CAchexia SCOre (CASCO). Staging Cancer Patients: The Use of miniCASCO as a Simplified ToolFrontiers in Physiology, 2017
- Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trialThe Lancet Haematology, 2017
- Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early‐phase oncology clinical trialsCancer, 2016
- Rapid screening for sarcopeniaJournal of Cachexia, Sarcopenia and Muscle, 2015
- Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2015Journal of Cachexia, Sarcopenia and Muscle, 2015
- Defining Sarcopenia in Terms of Incident Adverse OutcomesJournal of the American Medical Directors Association, 2015
- Mechanisms and treatment of cancer cachexiaNutrition, Metabolism and Cardiovascular Diseases, 2013
- Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patientsSupportive Care in Cancer, 2013